» Articles » PMID: 35946811

Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or MRNA Vaccines Against SARS-CoV-2 and the Relationship Between the Two Immune Responses

Abstract

We investigated how differences in age, sex, or vaccine type can affect humoral and cellular immune responses after vaccination with vector (ChAdOx1 nCoV-19), mix-and-match (first, ChAdOx1 nCoV-19, and second, BNT162b2), or mRNA (BNT162b2 or mRNA-1273) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Venous blood was collected from 573 subjects (vector, 396; mix-and-match, 96; and mRNA, 81) before the first vaccination (), 7 to 8 weeks (vector) or 3 to 4 weeks (mRNA) after the first vaccination (), and 3 to 4 weeks after the second vaccination (). The humoral and cellular immune responses were evaluated using Elecsys anti-SARS-CoV-2 (Roche), Alinity SARS-CoV-2 IgG II Quant (Abbott), cPass SARS-CoV-2 neutralization antibody detection (GenScript), and QuantiFERON SARS-CoV-2 (Qiagen) kits. At , the levels of the receptor-binding domain antibodies (RBD Ab) and neutralizing antibodies (NAb) decreased with aging, but interferon gamma release (IGR) levels increased. The RBD Ab, NAb, and IGR levels were higher in females than in males at and . The NAb levels were higher in the mix-and-match and mRNA vaccine groups than in the vector vaccine group at . The RBD Ab and IGR levels were higher in the mRNA vaccine group than in the vector or mix-and-match vaccine groups at . The optimal cutoffs for RBD Ab and NAb, which were used to determine the presence of T cell responses, were 5.7 binding antibody units per milliliter (BAU mL) and 12.0 IU mL, respectively. Age, sex, and vaccine type affected the humoral and cellular immune responses, and T cell responses could be estimated from RBD Ab and NAb levels. There have been few studies that comprehensively evaluated factors affecting immune responses and the correlation between humoral and cellular immune responses after vector, mix-and-match, and mRNA vaccines against SARS-CoV-2. Therefore, we analyzed the effects of age, sex, and the different vaccine regimens on the immune responses to vaccination against SARS-CoV-2. The correlation between humoral and cellular immune responses and the cutoffs were derived for RBD antibodies and neutralizing antibodies to predict the presence of the cellular immune responses. In this comprehensive study, we demonstrated that there were differences in the immune responses induced after vaccination depending on the age and sex of an individual. Among the three vaccine regimens, the mix-and-match and mRNA vaccines induced the most robust immune responses. Finally, the proposed optimal cutoffs for RBD and neutralizing antibodies may be useful for predicting cellular immune responses when assays for cellular immune responses are not available.

Citing Articles

Fast, Present and Future of the Concept of Spondyloarthritis.

Braun J Curr Rheumatol Rep. 2025; 27(1):15.

PMID: 39869233 DOI: 10.1007/s11926-024-01179-0.


Disparities in response to mRNA SARS-CoV-2 vaccines according to sex and age: A systematic review.

Bachmann M, Gultekin N, Stanga Z, Fehr J, Ulgur I, Schlagenhauf P New Microbes New Infect. 2025; 63():101551.

PMID: 39807161 PMC: 11726804. DOI: 10.1016/j.nmni.2024.101551.


Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza.

Cheng Z, Ma J, Zhao C Vaccines (Basel). 2025; 12(12.

PMID: 39772044 PMC: 11680418. DOI: 10.3390/vaccines12121382.


Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers.

Lee H, Ko G, Lee J, Bae H, Ryu J, Jung J Vaccines (Basel). 2025; 12(12.

PMID: 39772013 PMC: 11679843. DOI: 10.3390/vaccines12121350.


Antibody Response after Homologous and Heterologous Prime-Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort.

Adnan N, Haq M, Akter S, Sajal S, Islam M, Mou T Vaccines (Basel). 2024; 12(5).

PMID: 38793733 PMC: 11125736. DOI: 10.3390/vaccines12050482.


References
1.
Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

2.
Schiffner J, Backhaus I, Rimmele J, Schulz S, Mohlenkamp T, Klemens J . Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. Front Public Health. 2021; 9:732787. PMC: 8502872. DOI: 10.3389/fpubh.2021.732787. View

3.
Tehrani Z, Saadat S, Saleh E, Ouyang X, Constantine N, DeVico A . Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. PLoS One. 2020; 15(11):e0237828. PMC: 7605638. DOI: 10.1371/journal.pone.0237828. View

4.
Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F . Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel). 2021; 9(8). PMC: 8402499. DOI: 10.3390/vaccines9080857. View

5.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View